Bank of America cuts Stryker’s target by $70 citing weaker healthcare demand and inflation pressures in the medtech sector.
Bank of America reduced its price target for Stryker Corporation (SYK) to $380 from $450 while maintaining a Buy rating. The firm cited a softer healthcare utilization environment and a more conservative outlook for 2027 across the medical technology sector.
The adjustment reflects increased inflationary pressures and reduced margin expansion potential for medtech companies. Larger-cap names exposed to procedure volumes and cost inflation face lower earnings estimates. Stryker’s short interest stands at 1.63% of shares outstanding.
Stryker recently launched its Pangea Plating System in Europe, but the product announcement did not offset broader sector concerns.